Insmed Inc

NASDAQ:INSMUnited States

Insmed Incorporated is a biopharmaceutical company engaged in providing ARIKAYCE (amikacin liposome inhalation suspension) product, which is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1, which is developing for the treatment of patients with bronchiectasis, cystic fibrosis (CF) and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRS) and hidradenitis suppurativa (HS). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Contact Information

Headquarters

700 Us Highway 202/206BRIDGEWATER, NJ, United States 08807

Phone

908-977-9900

Fax

---

Executives

Chairman of the Board, President, Chief Executive Officer

William Lewis

Chief Financial Officer

Sara Bonstein

Chief Operating Officer

Roger Adsett

Chief People Strategy Officer

S. Nicole Schaeffer

Senior Vice President, General Counsel

Michael Smith